Reports for APOTEX INC
Company Name
APOTEX INC
Shortage reports
Actual shortage:
220 (7%)
Anticipated shortage:
0 (0%)
Avoided shortage:
10 (0%)
Resolved:
3124 (93%)
3354
Discontinuation Reports
To be discontinued:
25 (7%)
Discontinued:
342 (93%)
Reversed:
0 (0%)
367
146 (4%)
70 (29%)
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-CARVEDILOL | 6.25MG | TABLET | Resolved | 2019-10-09 | 2020-09-21 | 95853 |
| APO-CARVEDILOL | 3.125MG | TABLET | Resolved | 2020-06-10 | 2020-09-21 | 117348 |
| APO-CEFACLOR | 250MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19036 |
| APO-CEFACLOR | 500MG | CAPSULE | Actual shortage | 2017-08-13 | 2017-10-05 | 19039 |
| APO-CEFACLOR | 125MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19066 |
| APO-CEFACLOR | 250MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19069 |
| APO-CEFACLOR | 375MG | POWDER | Actual shortage | 2017-08-13 | 2017-10-05 | 19072 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2019-07-12 | 2019-11-25 | 89155 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-07-25 | 2024-08-09 | 233706 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-09-12 | 2024-10-11 | 237372 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2024-11-14 | 2024-12-13 | 243086 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2023-04-21 | 2024-03-08 | 190008 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2017-04-17 | 2017-04-25 | 7102 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2022-11-20 | 2022-12-23 | 175327 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2025-01-16 | 2025-02-28 | 247862 |
| APO-CEFADROXIL | 500MG | CAPSULE | Resolved | 2021-07-23 | 2021-10-12 | 142973 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-06-11 | 2021-08-06 | 140772 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2021-09-17 | 2021-10-25 | 145822 |
| APO-CEFEPIME | 1G | POWDER FOR SOLUTION | Resolved | 2024-01-19 | 2024-02-09 | 216672 |
| APO-CEFEPIME | 2G | POWDER FOR SOLUTION | Resolved | 2024-02-23 | 2024-03-01 | 220444 |
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-HYDROMORPHONE CR | 3MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110956 |
| APO-HYDROMORPHONE CR | 6MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110959 |
| APO-HYDROMORPHONE CR | 24MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110968 |
| APO-HYDROMORPHONE CR | 18MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110965 |
| APO-HYDROMORPHONE CR | 12MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110962 |
| APO-HYDROMORPHONE CR | 30MG | CAPSULE (EXTENDED RELEASE) | Discontinued | 2020-04-04 | 2020-04-04 | 110971 |
| APO-HYDROXYQUINE | 200MG | TABLET | Discontinued | 2018-09-07 | 2018-10-05 | 60524 |
| APO-IMIQUIMOD | Discontinued | 2019-11-26 | 2019-11-26 | 99672 | ||
| APO-IRBESARTAN | 75MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71231 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71234 |
| APO-IRBESARTAN | 150MG | TABLET | Discontinued | 2018-09-07 | 2018-12-28 | 60536 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2018-09-07 | 2018-09-15 | 60539 |
| APO-IRBESARTAN | 300MG | TABLET | Discontinued | 2019-01-04 | 2019-01-04 | 71237 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-02-23 | 40757 |
| APO-IRBESARTAN/HCTZ | 12.5MG 150MG | TABLET | Discontinued | 2018-02-23 | 2018-07-17 | 40760 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-02-23 | 2018-07-17 | 40763 | ||
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40766 |
| APO-IRBESARTAN/HCTZ | 25MG 300MG | TABLET | Discontinued | 2018-02-23 | 2018-09-15 | 40769 |
| APO-IRBESARTAN/HCTZ | Discontinued | 2018-09-07 | 2018-09-15 | 60548 | ||
| APO-LAMIVUDINE | 150MG | TABLET | Discontinued | 2018-09-07 | 2019-07-13 | 60557 |